A phase I, open label, non-randomised study to evaluate the pharmacokinetics and safety of Pralatrexate in patients with relapsed refractory advanced solid tumors and lymphoma with mild, moderate and severe renal impairment

A phase I, open label, non-randomised study to evaluate the pharmacokinetics and safety of Pralatrexate in patients with relapsed refractory advanced solid tumors and lymphoma with mild, moderate and severe renal impairment